A word från the CEO
“IDL Diagnostics has started 2026 with the strongest quarter in the company’s history, and the clear growth trend that we began to see toward the end of last year has continued. It is also very gratifying to be able to report both a positive result and positive cash flow for the quarter. Order intake continues to look very promising, and we have a clear plan to increase our presence in new markets, thereby enhancing the potential for continued growth over time.
Revenue in Q1 amounted to SEK 16.7 million, demonstrating continued strong demand for our products. Profit amounted to SEK 1.2 million and EBITDA came in at SEK 2.2 million, confirming that the business is profitable and that we are succeeding in maintaining a stable cost level. Cash flow of SEK 760 thousand strengthens our financial position and enables continued investment in development and expansion.”
Anders Hultman, CEO
Summary of the period January 1 – March 31
Highlights
IDL Diagnostics has formed a joint venture company together with its long-established partner, concile GmbH. Through this collaboration, IDL’s product portfolio will be broadened and marketed to a larger market.
IDL Diagnostics participated as an exhibitor at WHX Labs in Dubai together with concile. The main focus was on delivering multiple biomarkers across different POC readers and supporting testing for infection, cardiovascular diseases, oncology, hormones, and chronic diseases in a structured and platform-based manner.
IDL visited China and met with CLIA partners with the aim of gaining a better understanding of their challenges and how they can be supported in the launch and marketing of these products in the Chinese market.
Interim Report January 1 – March 31, 2026 (Link)